ELI LILLY & CO (1LLY.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1LLY - US5324571083 - Common Stock
1LLY.MI Key Statistics, Chart & Performance
The current stock price of 1LLY.MI is 871.1 EUR. In the past month the price increased by 6.84%. In the past year, price increased by 19.15%.
1LLY.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 11.08 | 204.47B | ||
| SAN.PA | SANOFI | 10.95 | 202.17B | ||
| 1SAN.MI | SANOFI | 10.95 | 202.21B | ||
| MRK.DE | MERCK KGAA | 13.84 | 51.33B | ||
| UCB.BR | UCB SA | 37.73 | 47.11B | ||
| UNC.DE | UCB SA | 38.66 | 48.28B | ||
| BAYN.DE | BAYER AG-REG | 6.8 | 35.67B | ||
| 1BAYN.MI | BAYER AG-REG | 6.29 | 33.02B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 24.42 | 10.06B | ||
| IPN.PA | IPSEN | 12.03 | 10.35B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 104.33 | 9.66B | ||
| VIRP.PA | VIRBAC SA | 19.81 | 2.88B |
Related stock screener links
About 1LLY.MI
Company Profile
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).
Company Info
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094
Indianapolis INDIANA US
Employees: 47000
Phone: 13172762000
ELI LILLY & CO / 1LLY.MI FAQ
What does 1LLY do?
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).
Can you provide the latest stock price for ELI LILLY & CO?
The current stock price of 1LLY.MI is 871.1 EUR. The price increased by 0.44% in the last trading session.
What is the dividend status of ELI LILLY & CO?
ELI LILLY & CO (1LLY.MI) has a dividend yield of 0.59%. The yearly dividend amount is currently 4.24.
What is the ChartMill rating of ELI LILLY & CO stock?
1LLY.MI has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Is ELI LILLY & CO (1LLY.MI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1LLY.MI.
Can you provide the growth outlook for ELI LILLY & CO?
The Revenue of ELI LILLY & CO (1LLY.MI) is expected to grow by 41.01% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for ELI LILLY & CO?
ELI LILLY & CO (1LLY.MI) has a market capitalization of 823.52B EUR. This makes 1LLY.MI a Mega Cap stock.
1LLY.MI Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to 1LLY.MI. When comparing the yearly performance of all stocks, 1LLY.MI is one of the better performing stocks in the market, outperforming 85.11% of all stocks.
1LLY.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 1LLY.MI. While 1LLY.MI has a great profitability rating, there are some minor concerns on its financial health.
1LLY.MI Financial Highlights
Over the last trailing twelve months 1LLY.MI reported a non-GAAP Earnings per Share(EPS) of 18.87. The EPS increased by 116.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 30.99% | ||
| ROA | 16.02% | ||
| ROE | 77.38% | ||
| Debt/Equity | 1.72 |
1LLY.MI Forecast & Estimates
37 analysts have analysed 1LLY.MI and the average price target is 913.35 EUR. This implies a price increase of 4.85% is expected in the next year compared to the current price of 871.1.
For the next year, analysts expect an EPS growth of 84.93% and a revenue growth 41.01% for 1LLY.MI